 Galera Therapeutics NASDAQ:GRTX was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The companys product candidate ... 